Fractyl Health Clinical Trial Data
Fractyl Health announced positive topline six-month results from its REMAIN-1 Pivotal Cohort study evaluating the Revita DMR System for weight maintenance after GLP-1 therapy discontinuation. The study met its six-month co-primary endpoint with high statistical significance (p=0.0023), showing that Revita participants retained 80% of their weight loss compared to 67% for the sham group. The company plans to submit a De Novo marketing application to the FDA in late Q4 2026 based on these results.